Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status By Ogkologos - December 17, 2024 115 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March New on NCI’s Websites for March 2025 MOST POPULAR Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival... January 9, 2024 Steroids May Limit the Effectiveness of Immunotherapy for Brain Cancer December 28, 2020 Shorter, More Intensive Radiation Safe after Surgery for Prostate Cancer November 18, 2021 Efficacy and Safety of Adjuvant Nivolumab for High-Risk Muscle-Invasive Urothelial Carcinoma... June 7, 2021 Load more HOT NEWS Disguising Cancer as an Infection Helps the Immune System Eliminate Tumors Happy Occupational Therapy Month Fostering Black leadership in cancer research New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma
